Warfarin dose requirement for patients with both VKORCI 3673A/A and CYP2C93/3 genotypes

被引：6

作者：

Fukuda, Tsuyoshi ^{[1
]}

Tanabe, Tomoko

Ohno, Masako

Tougou, Katsuhiko

Fujio, Yasushi

Azuma, Junichi

Yamamoto, Isamu

Takeda, Akira

机构：

[1] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Clin Evaluat med & Therapeut, Suita, Osaka 565, Japan

[2] Kita Osaka Police Hosp, Osaka, Japan

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2006年 / 80卷 / 05期

关键词：

D O I：

10.1016/j.clpt.2006.08.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：553 / 554

页数：2

共 5 条

[1] Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
Aquilante, CL
Langaee, TY
Lopez, LM
Yarandi, HN
Tromberg, JS
Mohuczy, D
Gaston, KL
Waddell, CD
Chirico, MJ
Johnson, JA
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 291 - 302
[2] Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy
Higashi, MK
Veenstra, DL
Kondo, LML
Wittkowsky, AK
Srinouanprachanh, SL
Farin, FM
Rettie, AE
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1690 - 1698
[3] Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population
Lee, SC
Ng, SS
Oldenburg, J
Chong, PY
Rost, S
Guo, JY
Yap, HL
Rankin, SC
Khor, HB
Yeo, TC
Ng, KS
Soong, R
Goh, BC
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (03) : 197 - 205
[4] Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients
Mushiroda, T
Ohnishi, Y
Saito, S
Takahashi, A
Kikuchi, Y
Saito, S
Shimomura, H
Wanibuchi, Y
Suzuki, T
Kamatani, N
Nakamura, Y
[J]. JOURNAL OF HUMAN GENETICS, 2006, 51 (03) : 249 - 253
[5] Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin:: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes
Takahashi, H
Kashima, T
Nomoto, S
Iwade, K
Tainaka, H
Shimizu, T
Nomizo, Y
Muramoto, N
Kimura, S
Echizen, H
[J]. PHARMACOGENETICS, 1998, 8 (05): : 365 - 373

← 1 →

Warfarin dose requirement for patients with both VKORCI 3673A/A and CYP2C9*3/*3 genotypes

Warfarin dose requirement for patients with both VKORCI 3673A/A and CYP2C93/3 genotypes